Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Completed · Phase 1/Phase 2 · Has a placebo group
Conditions studied: IgA Nephropathy
In brief
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
Key facts
- Study ID
- NCT03945318
- Run by
- Novartis Pharmaceuticals
- People needed
- 103
- Starts
- 2019-04-08
- Expected to finish
- 2026-06-10
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Amicis Research Center — Northridge, California, United States
- Colorado Kidney Care, P.C. — Denver, Colorado, United States
- Nephrology Associates of Central Florida — Orlando, Florida, United States
- Elixia Tampa, LLC — Tampa, Florida, United States
- New York Nephrology — Clifton Park, New York, United States
- Chris Sholer, P.C. — Oklahoma City, Oklahoma, United States
- Liberty Research Center — Arlington, Texas, United States
- Liberty Research Center — Dallas, Texas, United States
- Prolato Clinical Research Center — Houston, Texas, United States
- Soon Chun Hyang University Hospital Cheonan — Cheonan, Chungcheongnam-do, South Korea
- Hallym University Sacred Heart Hospital — Anyang-si, Gyeonggi-do, South Korea
- National Health Insurance Service Ilsan Hospital — Goyang-si, Gyeonggi-do, South Korea
- Hanyang University Guri Hostpital — Guri-si, Gyeonggi-do, South Korea
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea
- Liverpool University Hospital NHS Foundation Trust — Liverpool, England, United Kingdom
- PAREXEL Early Phase Clinical Unit — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.